Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →IgA-Enriched Phenotype Predicts Liver-Related Events in MASLD.
Clinical takeawayConsider measuring serum IgA in MASLD patients to identify those at higher risk of liver-related events, particularly if fibrosis staging alone does not fully explain disease progression. No clinical action yet: the therapeutic implications of IgA-targeted interventions remain to be tested in humans.
What it foundA high-risk MASLD subgroup with elevated IgA (≥ 318 mg/dL) had a 5-year liver-related event rate of 24.0% vs other subgroups, with a hazard ratio of 3.17 (95% CI 1.27-7.91) independent of fibrosis.
ContextChallenges the current fibrosis-centric risk stratification in MASLD by identifying an immune-driven high-risk phenotype independent of fibrosis stage, supported by multi-omics validation.
Emergingsuggested applicable standard· AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674.
Decision at stakeidentifying high-risk MASLD patients for liver-related events
AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674. · reviewed 2026-07-21 ↗Statins are safe and recommended in MASLD/MASH and compensated cirrhosis when indicated for cardiovascular risk reduction. Start per standard CV risk-based criteria with baseline LFTs; routine ALT monitoring on statin is not required and pre-existing transaminitis is not a contraindication. Hold or reduce only for clinically significant ALT elevation, severe muscle symptoms, or decompensated cirrhosis on an individualized basis.
Kimura T … Tanaka N · Journal of Hepatology · IF 40.1 · PubMed ↗